Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Whitehouse Labs, AMRI Increase E&L Expertise | Contract Pharma
Breaking News

Whitehouse Labs, AMRI Increase E&L Expertise

Adds staff and critical instrumentation to the E&L group

Whitehouse Labs has furthered its efforts to expand its Extractables and Leachables expertise. Within Albany Molecular Research, Inc. (AMRI), the company has doubled its scientific staff dedicated to Extractables / Leachables & Impurities this past year and plans for further growth in 2017.
 
Along with additional personnel, critical instrumentation has been added to the E&L group. Instruments have been identified to further develop novel solutions to meet E&L needs. AMRI has also assembled experts to help customers navigate the evolution of Extractables & Leachables expectations. These include material scientists, analytical chemists, biomedical engineers, toxicologists, and biocompatibility specialists.
 
Recently, many E/L and chemical characterization guidelines, as well as standards, have been revised to better address patient safety considerations in the pharma/biotech and medical device industries. These heightened requirements cover final fill, intermediate storage, and manufacturing systems.
 
Whitehouse Labs, a division of AMRI, offers analytical services providing support for manufacturing from analytical chemistry and material qualification to packaging optimization.

Visit AMRI at Interphex booth 1228.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters